Regeneron Pharmaceuticals reported solid second-quarter earnings surpassing expectations, yet faced multiple regulatory challenges. The FDA issued complete response letters delaying approvals of its bispecific antibody odronextamab for follicular lymphoma and three Eylea high-dose applications due to filling issues at a Catalent manufacturing facility, recently acquired by Novo Nordisk. The company anticipates future favorable FDA decisions once manufacturing problems are resolved. Despite these setbacks, Regeneron projects continued growth driven by existing products and maintains optimism for upcoming approvals.